Search Existing Participant Requests

The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.

Search Terms:

Investigator: Dr. Randall Bateman

Project Title: Evaluation of plasma tau and p-tau quantitation by mass spectrometry as biomarkers for differential diagnosis of AD and tauopathies

Date: October 12, 2018

Request ID: S1807

Aim 1: Use targeted mass spectrometry to design assays measuring tau isoforms in human plasma.

Aim 2: Assess the plasma tau assay’s accuracy for predicting CSF amyloid beta status (positive/negative) and amyloid PET status (positive/negative).

Aim 3:

Aim 4:

Investigator: Stephanie Schultz

Project Title: Physical Activity and Brain Metabolism Across Adulthood and Disease

Date: September 19, 2018

Request ID: S1806

Aim 1: Identify physical activity characteristics that are associated with a �beneficial� brain metabolism biomarker profile in aging and AD

Aim 2: Assess both direct and indirect effects of physical activity on cognitive functioning while accounting for participants� levels of global or regional AG (mediator)

Aim 3:

Aim 4:

Investigator: Jonathan Peelle & Mitch Sommers

Project Title: Hearing and speech in Alzheimer�s Disease

Date: June 16, 2018

Request ID: S1805

Aim 1: Validate a short hearing test using test-retest reliability in participants with CDRs of 0, 0.5, and 1

Aim 2: Conduct exploratory analyses between hearing, cognitive, and imaging data to support future grant applications

Aim 3:

Aim 4:

Investigator: Lilah Besser

Project Title: Longitudinal associations between neighborhood greenspace and brain aging in non-demented older adults

Date: June 4, 2018

Request ID: S1804

Aim 1: Examine associations between baseline neighborhood greenspace and cognitive decline in non-demented older adults, and whether these associations vary by a) race/ethnicity; and b) APOE genotype.

Aim 2: Investigate if baseline neighborhood greenspace is associated with hippocampal and white matter hyperintensity volume in non-demented older adults, and whether these associations vary by a) race/ethnicity; and b) APOE genotype.

Aim 3: Examine association between change in neighborhood greenspace over time and a) cognitive decline; b) hippocampal volume; and c) white matter hyperintensity volume.

Aim 4:

Investigator: Stark, Susan and Ances, Beau

Project Title: Falls: a marker of preclinical Alzheimer’s disease

Date: June 4, 2018

Request ID: S1803

Aim 1: To examine the relationship between falls and functional mobility in preclinical stages of AD

Aim 2: To examine a hypothesized model of central and peripheral mechanism(s) underlying falls and functional mobility in preclinical stages of AD.

Aim 3:

Aim 4:

Investigator: Julie M. Bugg

Project Title: Memory-Based Attentional Control: A Behavioral Biomarker for AD?

Date: April 13, 2018

Request ID: S1802

Aim 1: Compare the memory-based attentional control performance of cognitively healthy older adults with a Clinical Dementia Rating (CDR) of 0 to older adults in the earliest symptomatic stage of AD (CDR .5)

Aim 2: Provide a preliminary test of the hypothesis that memory-based attentional control may be sensitive to accumulating AD biomarkers in cognitively healthy older adults (CDR 0) by examining whether individuals with more preclinical AD pathology show greater impairment than those with less AD pathology

Aim 3: Examine relations between memory-based attentional control performance and theoretically targeted regional brain volumes (e.g., caudate and hippocampal volume)

Aim 4:

Investigator: Brian Gordon

Project Title: Neuroimaging markers of emerging dysfunction in preclinical Alzheimer Disease

Date: February 9, 2018

Request ID: S1801

Aim 1: Collect task-based functional magnetic resonance imaging data in older adults

Aim 2: Relate changes in task-based fMRI to Alzheimer disease biomarkers

Aim 3: Use task-based fMRI to predict longitudinal change

Aim 4: Relate task and resting state fMRI network structure

Investigator: Vlassenko/Goyal

Project Title: Aerobic Glycolysis: a Marker of Brain Resilience to Aging and Alzheimer’s Disease

Date: September 19, 2017

Request ID: S1707

Aim 1: Evaluate relationship between brain metabolism, structure and function across the adult lifespan and determine whether changes in aerobic glycolysis (AG) and ‘metabolic brain age’ correlate with regional and inter-individual changes in brain structure, connectivity, and cognitive assessments.

Aim 2: Determine whether baseline AG will correlate with cognitive assessments and MRI features of AD, and further predict MRI abnormalities and cognitive decline in the preclinical and symptomatic stages; and whether high AG will be associated with resilience to the progression of AD.

Aim 3:

Aim 4:

Investigator: Andrei Vlassenko

Project Title: Aerobic Glycolysis in the Development of Alzheimer�s Disease

Date: September 8, 2017

Request ID: S1706

Aim 1: Evaluate the role of AG as a function of preclinical and symptomatic stages of AD, and determine whether baseline AG predicts the rate of change in other biomarkers and cognitive measures, and if low baseline AG will be associated with the subsequent development of AD pathology and cognitive decline

Aim 2: Determine rate of change in AG in relation to rate of change in clinical assessments and biomarkers of AD; evaluate changes in AG and other PET measures of metabolism and circulation during the transition from no AD pathology to preclinical AD, and through the preclinical stages to symptomatic AD.

Aim 3:

Aim 4:

Investigator: Dmitriy Yablonskiy

Project Title: In vivo MRI Biomarkers of Microstructural Correlates of Brain Pathology in Preclinical and Early Alzheimer Disease

Date: July 21, 2017

Request ID: S1705

Aim 1: To develop a readily available, non-invasive quantitative in vivo MRI-based biomarker that can serve as a surrogate for Aβ accumulation in the brain

Aim 2: To establish specific quantitative and spatial patterns of GEPCI metrics abnormalities that would distinguish between normal brain, preclinical AD, and very mild AD

Aim 3: To test the hypothesis that the GEPCI metrics and/or changes in GEPCI metrics can be predictors of the disease progression

Aim 4: To validate GEPCI measurements against direct neuropathology